Service Insights
Key market players offer partial services and user-friendly sets to the stem cell scientists which assist them to
perform the engineering process without compromising the required pluripotency conditions.
Companies, such as Sigma-Aldrich Corporation and Thermo Fisher offer customized products for cutting the cell
lines at specific points, thereby boosting the growth contract based genome editing field.
Regional Insights
The market was dominated by North America owing to rising adoption of innovative and improved technologies
in the U.S. Moreover, higher occurrence rate of monogenic disorders is also accountable for the estimated
share.
For instance, cystic fibrosis befalls at an occurrence of 1 in 2,500 deliveries in the U.S thereby resulting in lung
and other organ damage. Furthermore, recently 1, 22,000 individuals necessitate organ transplant which is
gradually growing and anticipated to boost growth in the coming years. Asia Pacific is anticipated to witness
substantial progress over the forecast period due to rising research in personalized medicine in this sector.
Competitive Insights
Key market entities include Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, Editas Medicine, Sangamo,
Intellia Therapeutics Inc., CRISPR THERAPEUTICS and Caribou Biosciences Inc. Some companies are taking
benefit of authorizations from universities for the DNA editing tools application.
These participants are involved in various approaches such as cross-linking agreements, acquisitions, and in-
house research which permit the novel intellectual property licensing of innovative proteins.
Market Segment
Technology Outlook (Revenue, USD Million; 2014 - 2025)
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Others
Delivery Method Outlook (Revenue, USD Million; 2014 - 2025)